Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,300,086
  • Shares Outstanding, K 157,522
  • Annual Sales, $ 1,094 M
  • Annual Income, $ -139,310 K
  • 60-Month Beta 1.77
  • Price/Sales 2.97
  • Price/Cash Flow 33.38
  • Price/Book 3.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.48
  • Number of Estimates 5
  • High Estimate 0.59
  • Low Estimate 0.43
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +182.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.15 +9.40%
on 11/14/19
21.88 -4.25%
on 11/25/19
+1.25 (+6.35%)
since 11/06/19
3-Month
17.11 +22.44%
on 10/10/19
23.22 -9.78%
on 09/12/19
+0.69 (+3.41%)
since 09/06/19
52-Week
17.11 +22.44%
on 10/10/19
37.75 -44.50%
on 04/09/19
-13.82 (-39.75%)
since 12/06/18

Most Recent Stories

More News
Alcoholic Hepatitis Therapeutic Market Global Research and Clinical Survey 2019 to 2025

The Global Research report provides information regarding market size, share, trends, growth, cost structure, global market competition landscape, market drivers, challenges and opportunity, capacity,...

ALKS : 20.95 (+1.45%)
IMRN : 4.00 (+1.15%)
ICPT : 107.48 (-10.27%)
Sage Therapeutics' Depression Drug Fails in Study, Stock Down

Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.

ANIK : 57.48 (+0.75%)
ALKS : 20.95 (+1.45%)
SAGE : 64.46 (+7.11%)
VTGN : 0.44 (unch)
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

ALKS : 20.95 (+1.45%)
INVA : 12.91 (-0.46%)
ANIK : 57.48 (+0.75%)
RARX : 47.00 (+0.36%)
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

ANIK : 57.48 (+0.75%)
ALKS : 20.95 (+1.45%)
BDSI : 6.43 (-0.92%)
ZEAL : 32.87 (+5.83%)
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.

AZN : 47.68 (+0.13%)
JNJ : 140.38 (+0.59%)
AGN : 186.37 (+0.16%)
ALKS : 20.95 (+1.45%)
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ALKS : 20.95 (+1.45%)
SGMO : 11.66 (+0.56%)
Epizyme Announces FDA Committee Review of Tazemetostat NDA

Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.

GSK : 45.51 (+0.66%)
RHHBY : 38.5700 (+0.36%)
ALKS : 20.95 (+1.45%)
EPZM : 18.22 (+19.08%)
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU

The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.

BDSI : 6.43 (-0.92%)
AMRN : 22.45 (+2.93%)
ALKS : 20.95 (+1.45%)
ANIK : 57.48 (+0.75%)
Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1%

Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

DRNA : 26.63 (+0.45%)
ALKS : 20.95 (+1.45%)
Global Blood (GBT) in Focus: Stock Moves 5.2% Higher

Global Blood (GBT) shares rose more than 5% in the last trading session, amid huge volumes.

GBT : 79.35 (+4.20%)
ALKS : 20.95 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 21.32
1st Resistance Point 21.14
Last Price 20.95
1st Support Level 20.76
2nd Support Level 20.57

See More

52-Week High 37.75
Fibonacci 61.8% 29.87
Fibonacci 50% 27.43
Fibonacci 38.2% 24.99
Last Price 20.95
52-Week Low 17.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar